Electromed Inc (ELMD)

$17.25

+0.14

(+0.82%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $16.99
    $17.31
    $17.25
    downward going graph

    1.51%

    Downside

    Day's Volatility :1.85%

    Upside

    0.35%

    downward going graph
  • $9.53
    $18.60
    $17.25
    downward going graph

    44.75%

    Downside

    52 Weeks Volatility :48.76%

    Upside

    7.26%

    downward going graph

Returns

PeriodElectromed IncIndex (Russel 2000)
3 Months
16.63%
0.0%
6 Months
4.55%
0.0%
1 Year
54.85%
0.0%
3 Years
30.58%
-22.3%

Highlights

Market Capitalization
149.0M
Book Value
$5.16
Earnings Per Share (EPS)
0.58
PE Ratio
29.74
PEG Ratio
0.0
Wall Street Target Price
26.0
Profit Margin
9.41%
Operating Margin TTM
15.74%
Return On Assets TTM
8.39%
Return On Equity TTM
12.53%
Revenue TTM
54.7M
Revenue Per Share TTM
6.39
Quarterly Revenue Growth YOY
9.0%
Gross Profit TTM
36.5M
EBITDA
7.4M
Diluted Eps TTM
0.58
Quarterly Earnings Growth YOY
0.81
EPS Estimate Current Year
0.51
EPS Estimate Next Year
0.61
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 7 Wall street analysts offering stock ratings for Electromed Inc(by analysts ranked 0 to 5 stars)
Based on 7 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
6
6
6
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 50.72%

Current $17.25
Target $26.00

Company Financials

FY19Y/Y Change
Revenue
31.3M
↑ 9.07%
Net Income
2.0M
↑ 3.51%
Net Profit Margin
6.29%
↓ 0.34%
FY20Y/Y Change
Revenue
32.5M
↑ 3.74%
Net Income
4.2M
↑ 111.3%
Net Profit Margin
12.81%
↑ 6.52%
FY21Y/Y Change
Revenue
35.8M
↑ 10.12%
Net Income
2.4M
↓ 43.23%
Net Profit Margin
6.61%
↓ 6.2%
FY22Y/Y Change
Revenue
41.7M
↑ 16.51%
Net Income
2.3M
↓ 2.41%
Net Profit Margin
5.53%
↓ 1.08%
FY23Y/Y Change
Revenue
48.1M
↑ 15.38%
Net Income
3.2M
↑ 37.35%
Net Profit Margin
6.59%
↑ 1.06%
FY24Y/Y Change
Revenue
54.7M
↑ 13.83%
Net Income
5.2M
↑ 62.67%
Net Profit Margin
9.41%
↑ 2.82%
Q1 FY23Q/Q Change
Revenue
12.1M
↑ 2.89%
Net Income
1.1M
↑ 10.03%
Net Profit Margin
8.91%
↑ 0.58%
Q2 FY23Q/Q Change
Revenue
13.6M
↑ 12.79%
Net Income
1.0M
↓ 3.91%
Net Profit Margin
7.59%
↓ 1.32%
Q3 FY23Q/Q Change
Revenue
12.3M
↓ 9.46%
Net Income
155.0K
↓ 85.0%
Net Profit Margin
1.26%
↓ 6.33%
Q4 FY23Q/Q Change
Revenue
13.7M
↑ 11.08%
Net Income
1.7M
↑ 980.0%
Net Profit Margin
12.23%
↑ 10.97%
Q1 FY24Q/Q Change
Revenue
13.9M
↑ 1.33%
Net Income
1.5M
↓ 10.81%
Net Profit Margin
10.76%
↓ 1.47%
Q2 FY24Q/Q Change
Revenue
14.8M
↑ 6.93%
Net Income
1.8M
↑ 22.44%
Net Profit Margin
12.32%
↑ 1.56%
FY19Y/Y Change
Total Assets
29.4M
↑ 10.2%
Total Liabilities
3.6M
↓ 23.68%
FY20Y/Y Change
Total Assets
33.2M
↑ 13.25%
Total Liabilities
3.0M
↓ 17.26%
FY21Y/Y Change
Total Assets
37.1M
↑ 11.62%
Total Liabilities
4.7M
↑ 56.68%
FY22Y/Y Change
Total Assets
41.4M
↑ 11.47%
Total Liabilities
7.2M
↑ 53.23%
FY23Y/Y Change
Total Assets
45.8M
↑ 10.74%
Total Liabilities
8.1M
↑ 13.18%
FY24Y/Y Change
Total Assets
52.9M
↑ 15.45%
Total Liabilities
8.3M
↑ 2.47%
Q1 FY23Q/Q Change
Total Assets
42.8M
↑ 3.5%
Total Liabilities
6.4M
↑ 6.67%
Q2 FY23Q/Q Change
Total Assets
45.8M
↑ 6.92%
Total Liabilities
8.1M
↑ 26.24%
Q3 FY23Q/Q Change
Total Assets
44.1M
↓ 3.8%
Total Liabilities
5.8M
↓ 28.2%
Q4 FY23Q/Q Change
Total Assets
47.0M
↑ 6.58%
Total Liabilities
6.6M
↑ 13.31%
Q1 FY24Q/Q Change
Total Assets
48.9M
↑ 4.12%
Total Liabilities
6.4M
↓ 4.0%
Q2 FY24Q/Q Change
Total Assets
52.9M
↑ 8.15%
Total Liabilities
8.3M
↑ 31.19%
FY19Y/Y Change
Operating Cash Flow
2.6M
↑ 6.05%
Investing Cash Flow
-1.4M
↑ 142.51%
Financing Cash Flow
-851.2K
↓ 7367.35%
FY20Y/Y Change
Operating Cash Flow
4.2M
↑ 62.03%
Investing Cash Flow
-977.2K
↓ 29.53%
Financing Cash Flow
-548.0K
↓ 35.61%
FY21Y/Y Change
Operating Cash Flow
3.1M
↓ 26.68%
Investing Cash Flow
-448.0K
↓ 54.15%
Financing Cash Flow
-1.2M
↑ 122.43%
FY22Y/Y Change
Operating Cash Flow
-686.0K
↓ 122.29%
Investing Cash Flow
-1.5M
↑ 240.4%
Financing Cash Flow
-1.5M
↑ 25.1%
FY23Y/Y Change
Operating Cash Flow
1.3M
↓ 291.69%
Investing Cash Flow
-1.7M
↑ 12.52%
Financing Cash Flow
-380.0K
↓ 75.08%
Q1 FY23Q/Q Change
Operating Cash Flow
646.0K
↓ 52.64%
Investing Cash Flow
-558.0K
↑ 21.04%
Financing Cash Flow
-221.0K
↓ 2862.5%
Q2 FY23Q/Q Change
Operating Cash Flow
999.0K
↑ 54.64%
Investing Cash Flow
-441.0K
↓ 20.97%
Financing Cash Flow
38.0K
↓ 117.19%

Technicals Summary

Sell

Neutral

Buy

Electromed Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Electromed Inc
Electromed Inc
15.38%
4.55%
54.85%
30.58%
176.89%
Stryker Corporation
Stryker Corporation
12.3%
0.36%
24.19%
28.8%
65.26%
Boston Scientific Corp.
Boston Scientific Corp.
10.6%
20.32%
51.42%
80.93%
95.5%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
9.4%
-28.78%
-12.2%
-45.23%
-7.73%
Abbott Laboratories
Abbott Laboratories
3.57%
-5.84%
13.1%
-11.32%
35.19%
Medtronic Plc
Medtronic Plc
10.85%
5.57%
12.46%
-33.2%
-16.71%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Electromed Inc
Electromed Inc
29.74
29.74
0.0
0.51
0.13
0.08
NA
5.16
Stryker Corporation
Stryker Corporation
39.84
39.84
2.64
12.0
0.19
0.07
0.01
51.86
Boston Scientific Corp.
Boston Scientific Corp.
66.34
66.34
2.01
2.41
0.09
0.05
NA
13.85
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
26.3
26.3
3.2
2.69
0.22
0.12
NA
12.35
Abbott Laboratories
Abbott Laboratories
35.92
35.92
4.16
4.66
0.14
0.06
0.02
22.6
Medtronic Plc
Medtronic Plc
30.16
30.16
1.66
5.2
0.08
0.04
0.03
37.39
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Electromed Inc
Electromed Inc
Buy
$149.0M
176.89%
29.74
9.41%
Stryker Corporation
Stryker Corporation
Buy
$136.8B
65.26%
39.84
16.12%
Boston Scientific Corp.
Boston Scientific Corp.
Buy
$120.2B
95.5%
66.34
12.0%
Edwards Lifesciences Corp.
Edwards Lifesciences Corp.
Buy
$40.2B
-7.73%
26.3
23.74%
Abbott Laboratories
Abbott Laboratories
Buy
$198.1B
35.19%
35.92
13.65%
Medtronic Plc
Medtronic Plc
Buy
$115.3B
-16.71%
30.16
12.06%

Insights on Electromed Inc

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 12.32M → 14.83M (in $), with an average increase of 5.9% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 1.49M → 1.82M (in $), with an average increase of 18.3% per quarter

  • Vs BSX

    In the last 3 years, Boston Scientific Corp. has given 80.9% return, outperforming this stock by 50.3%

Company Information

electromed, inc. is a minnesota-based company (nyse mkt: elmd) and the innovative leader in the development, manufacture, and worldwide sales of the smartvest® airway clearance system. the patented system uses high frequency chest wall oscillation (hfcwo), a better-tolerated alternative to chest physiotherapy (cpt), to deliver vigorous, yet comfortable airway clearance treatment for patients battling the consequences of retained secretions. hfcwo has been clinically proven to clear the lungs of excess mucus, improve and reduce lung infections for individuals suffering from various conditions including atelectasis, copd, bronchiectasis, neuromuscular diseases, and cystic fibrosis. electromed, inc. is accredited by the joint commission and is iso 13485:2003 and iso 9001:2008 certified.

Organization
Electromed Inc
Employees
174
CEO
Mr. Bradley M. Nagel
Industry
Health Technology

Discover More

FAQs